Beth Mole is a Senior Health Reporter at Ars Technica. With a Ph.D. in microbiology and a background in science communication, Beth specializes in covering infectious diseases, public health, and microbes. She is known for her in-depth reporting on health-related topics and her ability to translate complex scientific concepts into accessible and engaging articles.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Beth Mole's coverage is heavily focused on healthcare and pharmaceuticals, with a significant emphasis on citing data, government announcements, and breaking news. Her articles often touch upon topics such as the pharmaceutical industry, FDA regulations, AI in healthcare, public health issues, and scientific developments.
Given her extensive coverage of healthcare-related topics with an emphasis on citing data and government announcements, Beth would likely be interested in receiving pitches from experts who can provide insightful analysis backed by credible data. Additionally, individuals or organizations involved in groundbreaking scientific research or those closely following regulatory changes within the healthcare sector may also capture her attention.
Considering that Beth focuses on national (United States) content but covers global health topics like MDMA therapy for PTSD treatment evaluated by the FDA as well as antibiotic resistance research; she may also consider perspectives from international experts whose insights have implications beyond U.S. borders.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Beth Mole
It's still unclear how long people will have to stay on the drugs to maintain the effects.
photo of Weight loss from Wegovy sustained for up to four years, trial shows image Enlarge / Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. (credit: Getty | Michael Siluk) A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and…
photo of Wegovy Can Keep Weight Off for at Least 4 Years, Research Shows image Users receiving weekly injections saw their weight fall, plateau, and stabilize over the course of a four-year trial—but it’s still unclear how long these effects last after stopping taking the drug.
By: Beth Mole
Of 13 children sickened, 7 hospitalized and 2 had life-threatening complications.
By: Beth Mole
Senators skeptical of legal trouble for harmless masking after moving to make it illegal.
By: Beth Mole
photo of It could soon be illegal to publicly wear a mask for health reasons in NC image Enlarge (credit: Getty | Spencer Platt) The North Carolina State Senate on Wednesday voted 30-15, along party lines, in favor of a Republican bill that would make it illegal for people in the state to wear a mask in public for health reasons. The bill is now moving to the House, where it could potentially see…
By: Beth Mole
The high dose of capsaicin paired with a heart defect appear to have contributed.
By: Beth Mole
photo of Autopsy finds teen died from ultra-spicy chip and heart defect, report says image Enlarge (credit: Sarah Dussault/MediaNews Group/The Mercury News via Getty Images) An autopsy report of a Massachusetts teen who tragically died hours after eating an ultra-spicy tortilla chip suggested that his death was due to the high dose of spice in the chip and a congenital heart defect, according to an…
By: Beth Mole
Prices would need to be dramatically slashed to avoid increasing the national deficit.
photo of “Outrageously” priced weight-loss drugs could bankrupt US health care image Enlarge / Packaging for Wegovy, manufactured by Novo Nordisk, is seen in this illustration photo. (credit: Getty | Jakub Porzycki) With the debut of remarkably effective weight-loss drugs, America's high obesity rate and its uniquely astronomical prescription drug pricing appear to be set on a catastrophic…
(833) 317-6278 
